A. Louie, M. Deziel, Weiguo Liu, Michael Drusano, T. Gumbo, G. Drusano (2005)
Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug ActivityAntimicrobial Agents and Chemotherapy, 49
A. Espinel-Ingroff (2003)
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.Revista iberoamericana de micologia, 20 4
Jorge Mora-Duarte, R. Betts, C. Rotstein, A. Colombo, Luis Thompson-Moya, Juanita Smietana, R. Lupinacci, C. Sable, N. Kartsonis, J. Perfect (2002)
Comparison of caspofungin and amphotericin B for invasive candidiasis.The New England journal of medicine, 347 25
T. Walsh, H. Teppler, G. Donowitz, J. Maertens, L. Baden, A. Dmoszyńska, O. Cornely, M. Bourque, R. Lupinacci, C. Sable, B. Depauw (2004)
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.The New England journal of medicine, 351 14
L. Ostrosky-Zeichner, J. Rex, P. Pappas, R. Hamill, R. Larsen, H. Horowitz, W. Powderly, N. Hyslop, C. Kauffman, J. Cleary, J. Mangino, Jeannette Lee (2003)
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrobial Agents and Chemotherapy, 47
F. Odds, M. Motyl, Roberto Andrade, J. Billé, E. Cantón, M. Cuenca‐Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. Fothergill, M. Ghannoum, R. Giacobbe, M. Gobernado, R. Handke, M. Laverdière, Wendy Lee-Yang, W. Merz, L. Ostrosky-Zeichner, J. Pemán, S. Perea, J. Perfect, M. Pfaller, L. Proia, J. Rex, M. Rinaldi, J. Rodríguez-Tudela, W. Schell, C. Shields, D. Sutton, P. Verweij, D. Warnock (2004)
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus SpeciesJournal of Clinical Microbiology, 42
N. Kartsonis, John Killar, L. Mixson, C. Hoe, C. Sable, K. Bartizal, M. Motyl (2005)
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment OutcomeAntimicrobial Agents and Chemotherapy, 49
G. Abruzzo, A. Flattery, C. Gill, Leopold Kong, Jeffrey Smith, V. Pikounis, J. Balkovec, Aileen Bouffard, J. Dropinski, H. Rosen, H. Kropp, F. BartizalKenneth (1997)
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosisAntimicrobial Agents and Chemotherapy, 41
M. Pfaller, L. Boyken, R. Hollis, S. Messer, S. Tendolkar, D. Diekema (2005)
In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to FluconazoleJournal of Clinical Microbiology, 43
A. Villanueva, E. Arathoon, E. Gotuzzo, R. Berman, M. Dinubile, C. Sable (2001)
A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 33 9
J. Graybill, R. Bocanegra, M. Luther, A. Fothergill, M. Rinaldi (1997)
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872Antimicrobial Agents and Chemotherapy, 41
M. Pfaller, D. Sheehan, J. Rex (2004)
Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for StandardizationClinical Microbiology Reviews, 17
P. Wayne (2002)
Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition
E. Bruck (1980)
National Committee for Clinical Laboratory Standards.Pediatrics, 65 1
G. Bonaventura, I. Spedicato, C. Picciani, D. D’Antonio, R. Piccolomini (2004)
In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic MalignanciesAntimicrobial Agents and Chemotherapy, 48
F. Barchiesi, A. Schimizzi, A. Fothergill, G. Scalise, Michael Rinaldi (1999)
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of Candida SpeciesEuropean Journal of Clinical Microbiology and Infectious Diseases, 18
M. Pfaller, D. Diekema, S. Messer, R. Hollis, R. Jones (2003)
In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant IsolatesAntimicrobial Agents and Chemotherapy, 47
E. Sarvikivi, O. Lyytikäinen, D. Soll, C. Pujol, M. Pfaller, M. Richardson, P. Koukila-Kähkölä, P. Luukkainen, H. Saxén (2005)
Emergence of Fluconazole Resistance in a Candida parapsilosis Strain That Caused Infections in a Neonatal Intensive Care UnitJournal of Clinical Microbiology, 43
B. Spellberg, S. Filler, J. Edwards (2006)
Current treatment strategies for disseminated candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 42 2
F. Barchiesi, A. Schimizzi, A. Fothergill, G. Scalise, M. Rinaldi (1999)
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of, 18
M. Pfaller, D. Diekema (2004)
Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatusJournal of Clinical Microbiology, 42
D. Denning (2003)
Echinocandin antifungal drugsThe Lancet, 362
K. Bartizal, C. Gill, G. Abruzzo, A. Flattery, L. Kong, Patricia Scott, Jeffrey Smith, Claire Leighton, Aileen Bouffard, J. Dropinski, J. Balkovec (1997)
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Antimicrobial Agents and Chemotherapy, 41
S. Hernandez, J. Lopez-Ribot, L. Najvar, D. McCarthy, R. Bocanegra, J. Graybill (2004)
Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida EsophagitisAntimicrobial Agents and Chemotherapy, 48
C. Douglas, J. D'Ippolito, G. Shei, M. Meinz, J. Onishi, J. Marrinan, W. Li, G. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, M. Kurtz (1997)
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitorsAntimicrobial Agents and Chemotherapy, 41
Antimicrobial Agents and Chemotherapy – Unpaywall
Published: Jul 26, 2006
Access the full text.
Sign up today, get DeepDyve free for 14 days.